BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32622946)

  • 21. Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis.
    Ouyang R; Li Z; Huang S; Liu J; Huang J
    Pain Med; 2020 Nov; 21(11):3224-3232. PubMed ID: 32488259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients.
    Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Kaira K; Minato K
    Thorac Cancer; 2022 Aug; 13(16):2301-2308. PubMed ID: 35790500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
    Katakami N; Oda K; Tauchi K; Nakata K; Shinozaki K; Yokota T; Suzuki Y; Narabayashi M; Boku N
    J Clin Oncol; 2017 Jun; 35(17):1921-1928. PubMed ID: 28445097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peripherally-active mu-opioid receptor antagonists for constipation in critically ill patients receiving opioids: A case-series and a systematic review and meta-analysis of the literature.
    Umbrello M; Venco R; Palandri C; Racagni M; Muttini S
    Neurogastroenterol Motil; 2023 Dec; 35(12):e14694. PubMed ID: 37869768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
    Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
    J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
    Wild J; Webster L; Yamada T; Hale M
    Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis.
    Nee J; Zakari M; Sugarman MA; Whelan J; Hirsch W; Sultan S; Ballou S; Iturrino J; Lembo A
    Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1569-1584.e2. PubMed ID: 29374616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors affecting the effect of naldemedine for opioid-induced constipation: a single-institution, retrospective analysis.
    Kanbayashi Y; Amaya F; Ueno H; Tabuchi Y; Ishikawa T; Takayama K; Taguchi T
    Pharmazie; 2021 Apr; 76(4):175-178. PubMed ID: 33849704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer.
    Kamiya T; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984494
    [No Abstract]   [Full Text] [Related]  

  • 30. Rational Design, Chemical Syntheses, and Biological Evaluations of Peripherally Selective Mu Opioid Receptor Ligands as Potential Opioid Induced Constipation Treatment.
    Huang B; Li M; Klongkumnuankarn P; Mendez RE; Gillespie JC; Stevens DL; Dewey WL; Selley DE; Zhang Y
    J Med Chem; 2022 Mar; 65(6):4991-5003. PubMed ID: 35255683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy.
    Stern EK; Brenner DM
    J Pain Res; 2018; 11():195-199. PubMed ID: 29391826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid withdrawal syndrome developing after long-term administration of naldemedine.
    Ishida M; Uchida N; Yabuno A; Hasegawa K; Mizunuma N; Takahashi T; Onishi H
    Palliat Support Care; 2022 Dec; 20(6):897-899. PubMed ID: 35543119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets.
    Simoneau II; Hamza MS; Mata HP; Siegel EM; Vanderah TW; Porreca F; Makriyannis A; Malan TP
    Anesthesiology; 2001 May; 94(5):882-7. PubMed ID: 11388542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Naldemedine versus placebo in opioid-induced constipation: a meta-analysis.
    Wobbe B; Gerner M; Köhne CH
    BMJ Support Palliat Care; 2024 Jan; 13(e3):e578-e584. PubMed ID: 36517204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancer pain.
    Liu JJ; Quinton SE; Brenner DM
    Pain Manag; 2020 Sep; 10(5):301-306. PubMed ID: 32552565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absorption, distribution, metabolism, and excretion of radiolabeled naldemedine in healthy subjects.
    Ohnishi S; Fukumura K; Kubota R; Wajima T
    Xenobiotica; 2019 Sep; 49(9):1044-1053. PubMed ID: 30351180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Naldemedine for the Use of Management of Opioid Induced Constipation.
    Urits I; Patel A; Kiernan HC; Clay CJ; Monteferrante N; Jung JW; Berger AA; Kassem H; Hasoon J; Kaye AD; Kaye AM; Viswanath O
    Psychopharmacol Bull; 2020 Jul; 50(3):97-118. PubMed ID: 32733114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naïve patients.
    van Malderen K; Halawi H; Camilleri M
    Neurogastroenterol Motil; 2018 May; 30(5):e13250. PubMed ID: 29119706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripherally acting μ-opioid antagonist for the treatment of opioid-induced constipation: Systematic review and meta-analysis.
    Nishie K; Yamamoto S; Yamaga T; Horigome N; Hanaoka M
    J Gastroenterol Hepatol; 2019 May; 34(5):818-829. PubMed ID: 30597600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis.
    Ishii K; Yamashita H; Yamaguchi M; Komatsu Y; Ryu E; Morishita S; Matsuo K; Kamada M; Ikeda T; Ashizawa K; Hara T
    Intern Med; 2020 Jan; 59(2):293-296. PubMed ID: 31534081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.